CN115201482A - Application of urine immunoglobulin lambda light chain and polypeptide fragment thereof in systemic lupus erythematosus - Google Patents

Application of urine immunoglobulin lambda light chain and polypeptide fragment thereof in systemic lupus erythematosus Download PDF

Info

Publication number
CN115201482A
CN115201482A CN202110395952.8A CN202110395952A CN115201482A CN 115201482 A CN115201482 A CN 115201482A CN 202110395952 A CN202110395952 A CN 202110395952A CN 115201482 A CN115201482 A CN 115201482A
Authority
CN
China
Prior art keywords
lambda light
ser
light chain
immunoglobulin lambda
urine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110395952.8A
Other languages
Chinese (zh)
Inventor
张曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202110395952.8A priority Critical patent/CN115201482A/en
Publication of CN115201482A publication Critical patent/CN115201482A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention provides an application of urine Immunoglobulin lambda light chain (Immunoglobulin lambda light chain) and polypeptide fragments thereof, in particular to an application of urine Immunoglobulin lambda light chain and polypeptide fragments thereof in preparation of medicines for diagnosing, differentially diagnosing, judging disease degree and activity, evaluating treatment effect, monitoring, prognosticating, researching mechanism and the like of Systemic Lupus Erythematosus (SLE). SLE is a diffuse connective tissue disease mediated by autoimmunity and highlighted by immunoinflammation, mostly presenting with hidden diseases and involving multiple systems of the body. The present invention demonstrates, through studies, that urinary immunoglobulin lambda light chains and polypeptide fragments thereof are expressed in SLE patients in elevated levels compared to healthy humans (normal controls). Can be used for various purposes of detecting SLE patients. The invention gives play to the advantages of non-invasive acquisition, large-scale repeated sampling and convenient preservation of the urine specimen, and detects the urine immunoglobulin lambda light chain and the polypeptide fragment thereof by using the urine specimen.

Description

Application of urine immunoglobulin lambda light chain and polypeptide fragment thereof in systemic lupus erythematosus
Technical Field
The invention relates to a new application of urine immunoglobulin lambda light chain and polypeptide fragment thereof, in particular to the application of urine immunoglobulin lambda light chain and polypeptide fragment thereof in SLE diagnosis, differential diagnosis, disease degree and activity judgment, treatment effect evaluation, monitoring, prognosis evaluation, mechanism research and the like.
Background
Systemic Lupus Erythematosus (SLE) is an autoimmune connective tissue disease that affects multiple organs throughout the body, and occurs well in women of childbearing age. According to epidemiological statistics research, the prevalence rate of SLE in China is 70/10 ten thousand, and the prevalence rate of SLE in women is up to 113/10 ten thousand. The reason for this disease is not clear, SLE is usually occult, the clinical manifestations are complex and various, and erythema with butterfly distribution on the nasal bridge and cheeks is the characteristic change of SLE. Skin damage from SLE also includes light sensitivity, hair loss, palmar and periungual erythema, discoid erythema, raynaud's phenomenon, and the like. In addition, the progression of SLE often involves multiple systems of the body, especially important visceral systems, such as lupus nephritis, neuropsychiatric lupus, pericardial effusion, blood and digestive system damage. Therefore, it is particularly important for the patients to diagnose, monitor the disease condition effectively and treat the disease in a targeted way.
Immunoglobulins (igs) are produced and secreted by plasma cells, the basic unit of which is a symmetrical structure consisting of two identical heavy chains (H chains) and two identical light chains (l chains). The immunoglobulin light chain can be divided into two types of kappa and lambda according to the difference of the structure, and has close relation with the immune system of the body. In the study, the content of immunoglobulin lambda light chain of the SLE patient is up-regulated compared with that of a healthy human group, and the content of immunoglobulin lambda light chain in urine is increased.
Compared with the common clinical blood sample, the urine can be collected in a large amount in a completely noninvasive, continuous and continuous way; without homeostatic regulation, more various and larger changes can be accumulated, and many pathophysiological changes of the body can be reflected in urine. Some protein polypeptides with relatively small molecular weight, such as hormones and cytokines, are excreted into urine quickly after entering blood, and the probability that the proteins and polypeptides are detected in urine is much higher than that in blood; before urine is collected, a possible protein degradation process in urine is completed, so that urine protein can be kept stable for a long time. In order to relieve the pain of multiple blood taking of the SLE patient, the experiment is expected to realize the diagnosis and disease monitoring of the SLE patient by painless, convenient, quick and easily repeated urine detection through the research of urine protein or polypeptide on the basis of the research of the methodology of the previous period, and also lays a foundation for the further research of the urine polypeptide detection kit.
Disclosure of Invention
The invention aims to provide applications of urine immunoglobulin lambda light chains and polypeptide fragments thereof in preparation of medicines for SLE diagnosis, differential diagnosis, disease degree and activity judgment, treatment effect evaluation, monitoring, prognosis evaluation, mechanism research and the like. <xnotran> , λ SEQ ID NO.1 (mawtvlllgl lshctgsvts yvltqppsvs vapgktasit cggnnigsks vhwyqqkpgq apvlvvydds drpsgiperf sgsnsgntat ltisrveagd eadyycqvwd sssdvvfggg tkltvlgqpk aapsvtlfpp sseelqanka tlvclisdfy pgavtvawka dsspvkagve tttpskqsnn kyaassylsl tpeqwkshrs yscqvthegs tvektvapte cs), SEQ ID NO.2 (mawiplflgv layctgsvas yeltqppsvs vspgqtasit cfgdklgdky sswyqqkpgq spllvlyqdt nrpsgiperf sgsnsgntat ltisetqamd egdyycqawd sntvvfgggt kltvlsqpka apsvtlfpps seelqankat lvclisdfyp gavtvawkad sspvkagvet ttpskqsnnk yaassylslt peqwkshrsy scqvthegst vektvaptec s), SEQ ID NO.3 (mawtplwltl ltlcigsvvs seltqdpavs valgqtvrit cqgdslrayy aswyqhkpgq apilviygen nrpsgipdrf sgsssgntas faitgaqaed eadyycnsrd ssgdqvlfgg gtkltvlgqp kaapsvtlfp psseelqank atlvclisdf ypgavtvawk adsspvkagv etttpskqsn nkyaassyls ltpeqwkshr syscqvtheg stvektvapt ecs), SEQ ID NO.4 (mawspllltl lahctgswaq svltqppsvs gapgqkitis csgtssniga ghhvhwyqqv pgtapklliy adnnrpsgvp drisgsksgt saslaitglr aedeadyycq sfdsslsgwv fggatkltvl gqpkaapsvt lfppsseelq ankatlvcli sdfypgavtv awkadsspvt agvetttpsk qsnnkyaass ylsltpeqwk shksyscqvt hegstvektv aptecs); </xnotran> Or an amino acid sequence which is derived from the amino acid sequences shown in SEQ ID NO.1 to 4 and has the same functions as the amino acid sequences shown in SEQ ID NO.1 to 4.
Preferably, the preparation is a detection kit for the urine immunoglobulin lambda light chain and polypeptide fragments thereof of the SLE patient.
Preferably, the kit comprises an immunological method of antigen-antibody reaction and kits thereof such as one or more of an aptamer antibody or antibody fragment capable of specifically binding to an immunoglobulin lambda light chain and polypeptide fragments thereof.
Preferably, the detection method comprises methods such as mass spectrometry for directly detecting the immunoglobulin lambda light chain and polypeptide fragments thereof and related kits thereof.
Preferably, the detection method comprises related nucleic acid detection methods for directly detecting the immunoglobulin lambda light chain and polypeptide fragments thereof and related kits.
Preferably, the kit further comprises a component selected from the group consisting of: the kit comprises a solid phase carrier, a diluent, a reference substance, a standard substance, a quality control substance, a detection antibody, a second antibody diluent, a luminescent reagent, a washing solution, a color development solution and a stop solution, wherein the solid phase carrier is any one or a combination of a plurality of the solid phase carrier, the diluent, the reference substance, the standard substance, the quality control substance, the detection antibody, the second antibody and the second antibody diluent.
Preferably, the standard comprises an immunoglobulin lambda light chain standard, a humanized tag antibody standard; preferably, the quality control product comprises: immunoglobulin lambda light chain quality control substances and humanized label antibody quality control substances; preferably, the solid support comprises: particles, microspheres, glass slides, test strips, plastic beads, liquid phase chips, micro-porous plates or affinity membranes and other carriers with the same functions.
Preferably, the solid phase carrier is made of any one of polyvinyl chloride, polystyrene, polyacrylamide and cellulose, and has similar functions.
The inventor firstly collects urine samples of healthy people and SLE patients, centrifugates for 5min at 4000r/min, absorbs supernatant, measures the concentration of extracted protein by a Bradford method, and carries out SDS-PAGE enzymolysis. The Label-free mass spectrometry of the urine samples was performed by the OrbitrapFasion type mass spectrometer. And performing quantitative calculation on the data obtained in the mass spectrum of the SLE group and the normal control group. The differential polypeptide is screened by using the difference of protein expression amount more than 1.5 times and P <0.05 as a reference standard through statistical test. Then, the inventors identify the differential polypeptide with statistical significance, and search by using a database to obtain the differential protein immunoglobulin lambda light chain. The inventor utilizes Western Blot immunoblotting test and German Siemens full-automatic special protein analyzer (BN-II system) to verify the immunoglobulin lambda light chain and the content thereof in the urine of SLR patients and healthy persons.
Compared with healthy people, the immunoglobulin lambda light chain and the polypeptide fragment thereof are high in expression in urine of SLE patients and have better consistency with clinical diagnosis. Therefore, the urine immunoglobulin lambda light chain and the polypeptide fragment thereof can be used for auxiliary diagnosis or disease monitoring of SLE.
The invention gives play to the advantages of non-invasive acquisition, large-scale repeated sampling and convenient preservation of the urine specimen, and detects the urine immunoglobulin lambda light chain and the polypeptide fragment thereof by using the urine specimen.
In order to make the aforementioned and other objects, features and advantages of the present invention comprehensible, preferred embodiments accompanied with figures are described in detail below.
Drawings
Figure 1 is a graph of urinary immunoglobulin lambda light chain and polypeptide fragments thereof content in SLE active patients, SLE inactive patients and healthy controls.
Figure 2 is a graph of the results of Western Blot immunoblotting experiments on urine immunoglobulin lambda light chains and polypeptide fragments thereof in SLE patients and healthy controls.
Detailed Description
Example 1Collection and processing of urine specimens
SLE patients were selected as SLE group and contemporary health examiners were selected as normal control group. 30ml samples of fresh morning urine were collected from each group of subjects after admission, and those who failed to urinate normally collected their morning urine from their catheters and placed in dry, clean containers. Centrifuging the collected urine specimen at 4000r/min for 5min, sucking supernatant, subpackaging 2ml per tube, and storing in a refrigerator at-80 ℃.
Example 2Mass spectrometry and screening of urine polypeptides
Extracting protein from the urine sample, and determining the concentration of the extracted protein. Mass spectrometry of urine samples was done by orbitrap type mass spectrometry. And performing quantitative calculation on data obtained in the mass spectrum of the experimental group and the normal control group. The difference analysis is carried out by adopting t-test in the comparison among groups, and the difference of the protein expression quantity is more than 1.5 times, and P <0.05 is used as a reference standard to screen the differential expression protein by statistical test.
Example 3Identification and analysis of differential Polypeptides
The used database is a Uniprot _ Homo database, the generated mass spectrum original file is processed by MaxQuant software, and the retrieval parameter setting is shown in Table 1.
TABLE 1 Max Quant software search parameter Table
Figure 736061DEST_PATH_IMAGE001
Example 4Validation of urine immunoglobulin lambda light chain
Qualitative and quantitative analysis of immunoglobulin lambda light chains in urine of SLE patients and healthy persons using Western Blot immunoblotting assay and German Siemens fully automated Special protein Analyzer (BN-II System)
Compared with healthy people, the immunoglobulin lambda light chain is highly expressed in urine of SLE patients, the content of the immunoglobulin lambda light chain in the urine of SLE patients and healthy people is shown in figure 1 by quantitative analysis of the immunoglobulin lambda light chain in the urine of SLE patients and SLE inactive patients and healthy controls by a German Siemens fully automatic Special protein analyzer (BN-II system), and the content of the immunoglobulin lambda light chain in the urine of SLE patients and healthy people is detected by using a Western Blot immunoblotting test, and the result is shown in figure 2. The expression of immunoglobulin lambda light chain in urine of normal control group and SLE group has significant difference.
Although the present invention has been described with respect to the preferred embodiments, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.
Sequence listing
<110> Zhang Man
Application of <120> urine immunoglobulin lambda light chain and polypeptide fragment thereof in systemic lupus erythematosus
<130> 1
<140> 21IGL-CN
<141> 2021-04-09
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 232
<212> PRT
<213> huamn urine
<400> 1
Met Ala Trp Thr Val Leu Leu Leu Gly Leu Leu Ser His Cys Thr Gly
1 5 10 15
Ser Val Thr Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala
20 25 30
Pro Gly Lys Thr Ala Ser Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser
35 40 45
Lys Ser Val His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu
50 55 60
Val Val Tyr Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe
65 70 75 80
Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val
85 90 95
Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser
100 105 110
Ser Asp Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln
115 120 125
Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu
130 135 140
Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr
145 150 155 160
Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys
165 170 175
Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr
180 185 190
Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His
195 200 205
Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys
210 215 220
Thr Val Ala Pro Thr Glu Cys Ser
225 230
<210> 2
<211> 231
<212> PRT
<213> huamn urine
<400> 2
Met Ala Trp Ile Pro Leu Phe Leu Gly Val Leu Ala Tyr Cys Thr Gly
1 5 10 15
Ser Val Ala Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser
20 25 30
Pro Gly Gln Thr Ala Ser Ile Thr Cys Phe Gly Asp Lys Leu Gly Asp
35 40 45
Lys Tyr Ser Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Leu Leu
50 55 60
Val Leu Tyr Gln Asp Thr Asn Arg Pro Ser Gly Ile Pro Glu Arg Phe
65 70 75 80
Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Glu Thr
85 90 95
Gln Ala Met Asp Glu Gly Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Asn
100 105 110
Thr Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Ser Gln Pro
115 120 125
Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu
130 135 140
Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro
145 150 155 160
Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala
165 170 175
Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala
180 185 190
Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg
195 200 205
Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr
210 215 220
Val Ala Pro Thr Glu Cys Ser
225 230
<210> 3
<211> 233
<212> PRT
<213> huamn urine
<400> 3
Met Ala Trp Thr Pro Leu Trp Leu Thr Leu Leu Thr Leu Cys Ile Gly
1 5 10 15
Ser Val Val Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala
20 25 30
Leu Gly Gln Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ala
35 40 45
Tyr Tyr Ala Ser Trp Tyr Gln His Lys Pro Gly Gln Ala Pro Ile Leu
50 55 60
Val Ile Tyr Gly Glu Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe
65 70 75 80
Ser Gly Ser Ser Ser Gly Asn Thr Ala Ser Phe Ala Ile Thr Gly Ala
85 90 95
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ser Ser
100 105 110
Gly Asp Gln Val Leu Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
115 120 125
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
130 135 140
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
145 150 155 160
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
165 170 175
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
180 185 190
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
195 200 205
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
210 215 220
Lys Thr Val Ala Pro Thr Glu Cys Ser
225 230
<210> 4
<211> 236
<212> PRT
<213> huamn urine
<400> 4
Met Ala Trp Ser Pro Leu Leu Leu Thr Leu Leu Ala His Cys Thr Gly
1 5 10 15
Ser Trp Ala Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala
20 25 30
Pro Gly Gln Lys Ile Thr Ile Ser Cys Ser Gly Thr Ser Ser Asn Ile
35 40 45
Gly Ala Gly His His Val His Trp Tyr Gln Gln Val Pro Gly Thr Ala
50 55 60
Pro Lys Leu Leu Ile Tyr Ala Asp Asn Asn Arg Pro Ser Gly Val Pro
65 70 75 80
Asp Arg Ile Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile
85 90 95
Thr Gly Leu Arg Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Phe
100 105 110
Asp Ser Ser Leu Ser Gly Trp Val Phe Gly Gly Ala Thr Lys Leu Thr
115 120 125
Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro
130 135 140
Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile
145 150 155 160
Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser
165 170 175
Ser Pro Val Thr Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser
180 185 190
Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln
195 200 205
Trp Lys Ser His Lys Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser
210 215 220
Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser
225 230 235

Claims (9)

1. The urine immunoglobulin lambda light chain and the polypeptide fragment thereof are applied to the preparation of SLE diagnosis, differential diagnosis, disease degree and activity judgment, treatment effect evaluation, monitoring, prognosis evaluation, mechanism research and the like.
2. The use of claim 1, wherein the urine immunoglobulin lambda light chain has an amino acid sequence shown as SEQ ID NO 1 to 4; or an amino acid sequence which is derived from the amino acid sequences shown in SEQ ID NO.1 to 4 and has the same function with the amino acid sequences shown in SEQ ID NO.1 to 4.
3. The use of claim 1, wherein the agent is a detection kit for urine immunoglobulin lambda light chains and polypeptide fragments thereof from SLE patients.
4. Use according to claim 3, wherein the kit comprises an immunological method of antigen-antibody reaction and kits thereof such as one or more of aptamer antibodies or antibody fragments capable of specifically binding to immunoglobulin lambda light chains and polypeptide fragments thereof.
5. The use of claim 3, wherein the detection method comprises mass spectrometry and related kits for directly detecting immunoglobulin lambda light chains and polypeptide fragments thereof.
6. The use of claim 3, wherein the detection method comprises a method for directly detecting the lambda light chain of immunoglobulin and its polypeptide fragment or its related nucleic acid, and its related kit.
7. The use according to claim 3, wherein the kit further comprises a component selected from the group consisting of: the kit comprises a solid phase carrier, a diluent, a reference substance, a standard substance, a quality control substance, a detection antibody, a second antibody diluent, a luminescent reagent, a washing solution, a color development solution and a stop solution, wherein the solid phase carrier is any one or a combination of a plurality of the solid phase carrier, the diluent, the reference substance, the standard substance, the quality control substance, the detection antibody, the second antibody and the second antibody diluent.
8. The use of claim 7, wherein the standard comprises an immunoglobulin lambda light chain standard, a humanized tag antibody standard; preferably, the quality control product comprises: immunoglobulin lambda light chain control product and humanized label antibody quality control product; preferably, the solid support comprises: particles, microspheres, glass slides, test strips, plastic beads, liquid phase chips, micro-porous plates or affinity membranes and other carriers with the same functions.
9. The use of claim 8, wherein the solid phase carrier is made of any one of polyvinyl chloride, polystyrene, polyacrylamide, cellulose, and carriers with similar functions.
CN202110395952.8A 2021-04-13 2021-04-13 Application of urine immunoglobulin lambda light chain and polypeptide fragment thereof in systemic lupus erythematosus Pending CN115201482A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110395952.8A CN115201482A (en) 2021-04-13 2021-04-13 Application of urine immunoglobulin lambda light chain and polypeptide fragment thereof in systemic lupus erythematosus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110395952.8A CN115201482A (en) 2021-04-13 2021-04-13 Application of urine immunoglobulin lambda light chain and polypeptide fragment thereof in systemic lupus erythematosus

Publications (1)

Publication Number Publication Date
CN115201482A true CN115201482A (en) 2022-10-18

Family

ID=83571622

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110395952.8A Pending CN115201482A (en) 2021-04-13 2021-04-13 Application of urine immunoglobulin lambda light chain and polypeptide fragment thereof in systemic lupus erythematosus

Country Status (1)

Country Link
CN (1) CN115201482A (en)

Similar Documents

Publication Publication Date Title
CN115201482A (en) Application of urine immunoglobulin lambda light chain and polypeptide fragment thereof in systemic lupus erythematosus
CN113777314A (en) Application of urine ankle protein 1 and polypeptide fragment thereof in burn
CN117147861A (en) Application of urine alpha-trypsin inhibitor heavy chain H2 and polypeptide fragment thereof in systemic lupus erythematosus
CN114252605A (en) Application of urine myeloperoxidase and polypeptide fragment thereof in allergic diseases
CN117147847A (en) Application of urine immunoglobulin kappa light chain and polypeptide fragment thereof in systemic lupus erythematosus
CN117147862A (en) Application of urine alpha-trypsin inhibitor heavy chain H3 and polypeptide fragment thereof in systemic lupus erythematosus
CN117147860A (en) Application of urine heparin cofactor II and polypeptide fragment thereof in systemic lupus erythematosus
CN117233396A (en) Application of urine extracellular matrix protein 1 and polypeptide fragment thereof in systemic lupus erythematosus
CN113759121A (en) Application of urine immunoglobulin kappa variable region 3D-7 and polypeptide fragment thereof in burn
CN116794315A (en) Application of urine alpha-trypsin inhibitor heavy chain H4 and polypeptide fragment thereof in systemic lupus erythematosus
CN113804895A (en) Application of urine immunoglobulin heavy chain variable region 3-7 and polypeptide fragment thereof in burn
CN113777313A (en) Application of urine vitamin K-dependent protein S and polypeptide fragment thereof in burn
CN114252628A (en) Application of urine regeneration protein and polypeptide fragment thereof in allergic diseases
CN113777316A (en) Application of urine C4b binding protein alpha chain and polypeptide fragment thereof in burn
CN113777305A (en) Application of urine monoadenosine diphosphate ribosyltransferase and polypeptide fragment thereof in burn
CN114252603A (en) Urine catalase and application of polypeptide fragment thereof in allergic diseases
CN113759125A (en) Urinary uteroglobin and application of polypeptide fragments thereof in burn
CN114252626A (en) Application of urinary laminin-1 and polypeptide fragment thereof in allergic diseases
CN114636823A (en) Application of urine hepcidin regulatory protein and polypeptide fragment thereof in allergic diseases
CN113804890A (en) Application of urine programmed cell death 6 interaction protein and polypeptide fragment thereof in burn
CN114113640A (en) Application of urine blood coagulation factor IX and polypeptide fragment thereof in burn
CN114113621A (en) Urine guanine nucleotide binding protein subunit alpha-13 and application of polypeptide fragment thereof in burn
CN113777304A (en) Application of urine plasminogen and polypeptide fragment thereof in burn
CN113759122A (en) Application of urine protein Z and polypeptide fragment thereof in burn
CN113777302A (en) Application of urine complement factor D and polypeptide fragment thereof in burn

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination